# Dapagliflozin Evaluation on Atrial Fibrillation Patients Followed Cox Maze IV Procedure

Study · id `cardio:ct-nct05816733` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05816733](<https://clinicaltrials.gov/study/NCT05816733>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05816733

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 348 participants.

## Technical summary

Registry record NCT05816733. Randomized; double masking; primary purpose prevention. Start 2023-09-01 (actual); primary completion 2024-06-07 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 348 participants (planned count; ClinicalTrials.gov record NCT05816733, source copy `cardio:ctgov-nct05816733-2023-11-29`, retrieved 2026-10-26)
- Started: 2023-09-01 (actual) (ClinicalTrials.gov record NCT05816733, source copy `cardio:ctgov-nct05816733-2023-11-29`, retrieved 2026-10-26)
- Primary completion: 2024-06-07 (anticipated) (ClinicalTrials.gov record NCT05816733, source copy `cardio:ctgov-nct05816733-2023-11-29`, retrieved 2026-10-26)
- Completion: 2024-08-07 (anticipated) (ClinicalTrials.gov record NCT05816733, source copy `cardio:ctgov-nct05816733-2023-11-29`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05816733, source copy `cardio:ctgov-nct05816733-2023-11-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05816733-2023-11-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: Dapagliflozin Evaluation on Atrial Fibrillation Patients Followed Cox Maze IV Procedure
- Acronym: DETAIL-CMIV
- Condition: Atrial Fibrillation Recurrence
- Condition: Cox Maze IV
- Condition: Atrial Fibrillation
- Condition: Patients With or Without Heart Failure and Diabetes
- Intervention (Drug): Dapagliflozin
- Intervention (Drug): Placebo
- Lead sponsor: Kun Hua
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention name matches this record: Dapagliflozin (`cardio:dapagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)

## Provenance

Content hash: 844cb087c72fa6c30aacd5bffbfb80ac60e72cce59bd1f0f9a03bc21ead6ea6f
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
